Olga Montvida

Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study.

Digsu N Koye, Olga Montvida, Sanjoy Ketan Paul

Journal article  |  2020  |  Drugs

BACKGROUND: Third-line antidiabetic drug (ADD) intensification patterns and glycemic control post intensification in type 2 diabet..

Cardiovascular Risk Factor Burden in People With Incident Type 2 Diabetes in the US Receiving Antidiabetic and Cardioprotective Therapies

Olga Montvida, Xiaoling Cai, Sanjoy K Paul

Journal article  |  2019  |  Diabetes Care

Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes

O Montvida, JB Green, J Atherton, SK Paul

Journal article  |  2019  |  Diabetic Medicine

Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study

Olga Montvida, Jonathan E Shaw, Lawrence Blonde, Sanjoy K Paul

Journal article  |  2018  |  Diabetes, Obesity and Metabolism

Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data

Sanjoy Ketan Paul, Olga Montvida, Jennie H Best, Sara Gale, Attila Pethoe-Schramm, Khaled Sarsour

Journal article  |  2018  |  Seminars in Arthritis and Rheumatism

Long-term Trends in Antidiabetes Drug Usage in the US: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes

Olga Montvida, Jonathan Shaw, John J Atherton, Frances Stringer, Sanjoy K Paul

Journal article  |  2018  |  Diabetes Care

Weight gain in insulin-treated patients by body mass index category at treatment initiation: new evidence from real-world data in patients with type 2 diabetes

SK Paul, JE Shaw, O Montvida, K Klein

Journal article  |  2016  |  Diabetes, Obesity and Metabolism